Health ❯Healthcare ❯Clinical Trials ❯Phase 3 Trials

Efficacy Studies

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

The new option becomes available in the U.S. on Oct. 6 for patients transitioning after 18 months of IV therapy.

EU Backs First Twice-Yearly Injectable for HIV Prevention

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

FDA Approves Vyalev for Advanced Parkinson's Disease Treatment

New Biannual HIV Injection Reduces Infection Risk by 96%

New HIV Prevention Drug Shows 100% Efficacy in Women